XyloCor closes $17M Series A round to develop gene therapy for refractory angina
The Philadelphia-based company has an IND open with the FDA and plans to begin its clinical trial in the first half of next year.
Artios raises $84M for developing cancer drugs targeting DNA repair pathway
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.
presented by
Immune Support on Demand: Ranking the Top Mobile IV Therapy Companies
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.